VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
+7.59%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.27B
AUM Growth
+$1.27B
(-5.5%)
Cap. Flow
-$177M
Cap. Flow
% of AUM
-13.98%
Top 10 Holdings %
Top 10 Hldgs %
50.64%
Holding
85
New
23
Increased
22
Reduced
17
Closed
16
Top Buys
| 1 |
Insmed
INSM
|
$62.1M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$49.5M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$33.8M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$28.1M |
| 5 |
Structure Therapeutics
GPCR
|
$25.9M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$74.7M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$66.8M |
| 3 |
Globus Medical
GMED
|
$61.6M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$58.3M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$49.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Insmed
INSM
$28.8B
| $117M | 8.86% | 1,600,000 +850,000 | +113% | +$62.1M |
|
|
2
Jazz Pharmaceuticals
JAZZ
$7.75B
| $100M | 7.6% | 900,000 -600,000 | -40% | -$66.8M |
|
3
Cytokinetics
CYTK
$4.23B
| $79.2M | 6.01% | 1,500,000 -575,000 | -28% | -$30.4M |
|
|
NARI
4
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $63.9M | 4.85% | 1,550,000 +1,200,000 | +343% | +$49.5M |
|
5
Arcellx
ACLX
$3.85B
| $56.4M | 4.27% | 675,000 | – | – |
|
|
6
Structure Therapeutics
GPCR
$1.11B
| $50.5M | 3.83% | 1,150,000 +590,000 | +105% | +$25.9M |
|
7
KalVista Pharmaceuticals
KALV
$678M
| $46.3M | 3.51% | 4,000,000 +1,700,000 | +74% | +$19.7M |
|
8
Astria Therapeutics
ATXS
$349M
| $44M | 3.34% | 4,000,000 +750,000 | +23% | +$8.26M |
|
9
Immatics
IMTX
$619M
| $42.8M | 3.24% | 3,750,000 +1,000,000 | +36% | +$11.4M |
|
|
10
Ultragenyx Pharmaceutical
RARE
$2.89B
| $41.7M | 3.16% | 750,000 -1,050,000 | -58% | -$58.3M |
|
|
11
Ascendis Pharma
ASND
$11.8B
| $37.3M | 2.83% | 250,000 -500,000 | -67% | -$74.7M |
|
12
Soleno Therapeutics
SLNO
$3.6B
| $36.4M | 2.76% | 720,000 -480,000 | -40% | -$24.2M |
|
13
Day One Biopharmaceuticals
DAWN
$769M
| $34.8M | 2.64% | 2,500,000 +1,250,000 | +100% | +$17.4M |
|
14
Savara
SVRA
$567M
| $34.3M | 2.6% | 8,090,000 +1,600,000 | +25% | +$6.78M |
|
|
15
Agios Pharmaceuticals
AGIO
$2.19B
| $33.8M | 2.56% | +760,000 | New | +$33.8M |
|
16
Xenon Pharmaceuticals
XENE
$2.98B
| $32.5M | 2.46% | 825,000 +300,000 | +57% | +$11.8M |
|
|
17
BioMarin Pharmaceuticals
BMRN
$11.2B
| $28.1M | 2.13% | +400,000 | New | +$28.1M |
|
18
uniQure
QURE
$896M
| $23.4M | 1.78% | 4,750,000 | – | – |
|
19
Janux Therapeutics
JANX
$1.37B
| $22M | 1.67% | 485,000 -240,000 | -33% | -$10.9M |
|
20
Black Diamond Therapeutics
BDTX
$157M
| $21.9M | 1.66% | 5,028,500 +2,928,500 | +139% | +$12.7M |
|
21
Solid Biosciences
SLDB
$427M
| $19.5M | 1.48% | 2,800,000 +135,000 | +5% | +$941K |
|
22
Edwards Lifesciences
EW
$47.8B
| $18.1M | 1.38% | +275,000 | New | +$18.1M |
|
23
Gilead Sciences
GILD
$140B
| $16.8M | 1.27% | +200,000 | New | +$16.8M |
|
24
Liquidia Corp
LQDA
$2.38B
| $15M | 1.14% | 1,500,000 -330,000 | -18% | -$3.3M |
|
25
Agilent Technologies
A
$35.7B
| $14.8M | 1.13% | +100,000 | New | +$14.8M |
|